BioSpace News Archive

Ceapro Inc. announced they are receiving advisory services and up to $480,000 in funding from the National Research Council of Canada Industrial Research Assistance Program to support Ceapro’s project entitled, “Boosting innovation capacity of Pressurized Gas eXpanded Technology towards pharmaceutical applications.”

Spectral Medical Inc. (“Spectral” or the “Company”) (TSX: EDT), today announced that the United States Federal Food and Drug Agency (“FDA”) has approved a protocol amendment to its Tigris trial allowing for the use of sequential organ failure assessment (“SOFA”) scoring as inclusion criteria into the study.